Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma (IL6-OSCC)
Salivary Interleukin-6 Levels and Interleukin Gene Polymorphisms for the Biological Stratification of Locoregional Progression in Oral Squamous Cell Carcinoma (OSCC): A Multicentre Observational Cross-Sectional Study
This observational study will evaluate whether salivary interleukin-6 levels and selected interleukin gene polymorphisms are associated with regional lymph node involvement in patients with oral squamous cell carcinoma.
Adult patients with histologically confirmed oral squamous cell carcinoma will be enrolled before receiving any cancer-specific treatment. Participants will be classified into two groups according to the presence or absence of regional lymph node metastasis: OSCC N0M0 and OSCC N+M0.
The study does not involve any experimental treatment and does not change the standard diagnostic or therapeutic pathway. Each participant will provide a saliva sample using a sterile absorbent swab. The saliva sample will be used to measure interleukin-6 levels. Available biological material will also be used to analyze selected interleukin gene polymorphisms, including IL6, IL1B, IL10, IL8/CXCL8, and IL1RN.
The aim of the study is to explore whether these salivary and genetic markers may help characterize different biological patterns of locoregional progression in oral squamous cell carcinoma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Oral squamous cell carcinoma is characterized by variable biological behavior, including different patterns of regional lymph node involvement. Regional lymph node metastasis is one of the main prognostic factors in this disease. However, patients with similar clinicopathological characteristics may show different patterns of locoregional progression, suggesting that additional biological markers may help describe tumor behavior.
This multicentre observational cross-sectional study will investigate salivary interleukin-6 and selected interleukin gene polymorphisms in adult patients with histologically confirmed oral squamous cell carcinoma. Participants will be enrolled before any cancer-specific treatment and classified according to regional lymph node status as OSCC N0M0 or OSCC N+M0.
Saliva will be collected using a standardized sterile absorbent swab procedure. Salivary interleukin-6 levels will be quantified and expressed as pg/mL. Selected interleukin-related genetic polymorphisms, including IL6, IL1B, IL10, IL8/CXCL8, and IL1RN, will be analyzed from available biological material using validated molecular biology methods.
The primary objective is to compare salivary interleukin-6 levels between patients without regional lymph node metastasis and patients with regional lymph node metastasis. Secondary objectives include evaluating the association between nodal status and interleukin gene polymorphisms, and exploring the relationship between these polymorphisms and salivary interleukin-6 levels.
No experimental treatment will be administered, and participation will not modify the standard diagnostic or therapeutic management of oral squamous cell carcinoma.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Matteo Pellegrini, DDS
- Número de telefone: +39 0382 516209
- E-mail: matteo.pellegrini02@universitadipavia.it
Locais de estudo
-
-
Lombardy
-
Milan, Lombardy, Itália, 20122
- Maxillo-Facial Surgery and Dental Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Contato:
- Giada Anna Beltramini, Associate Professor
- Número de telefone: +39 02 5503 4422
- E-mail: giada.beltramini@policlinico.mi.it
-
Pavia, Lombardy, Itália, 27100
- Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia
-
Contato:
- Matteo Pellegrini, DDS
- Número de telefone: +39 0382 516209
- E-mail: matteo.pellegrini02@universitadipavia.it
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 18 years or older
- Histopathologically confirmed diagnosis of oral squamous cell carcinoma of the oral cavity
- Oral squamous cell carcinoma site excluding oropharyngeal sites
- Defined regional lymph node status allowing classification as OSCC N0M0 or OSCC N+M0
- Absence of distant metastasis, classified as M0
- Saliva sample collection feasible before any OSCC-specific oncological treatment, including surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy
- Suitability for saliva collection using a standardized absorbent swab
- Availability of biological material for genotyping
- Ability to provide written informed consent for study participation, biological sampling, and genetic analysis
Exclusion Criteria:
- Age younger than 18 years
- Oral squamous cell carcinoma involving oropharyngeal sites
- Presence of distant metastasis
- Previous OSCC-specific oncological treatment before saliva sample collection
- Acute infection at the time of sampling or within the previous 2 weeks
- Active or inadequately controlled systemic autoimmune or inflammatory disease that may significantly alter cytokine profiles
- Systemic immunosuppressive or immunomodulatory therapy within the previous 4 to 8 weeks
- Recent oncological treatment for malignancies other than OSCC within the previous 6 months, if considered potentially interfering with the immune-inflammatory profile
- Clinically significant acute oral infection or inflammatory process at the time of sampling
- Active oral bleeding or evident blood contamination of the salivary swab Invasive dental procedures within the previous 2 weeks
- Systemic antibiotic therapy within the previous 2 weeks
- Inability to provide written informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
OSCC N0M0
Adult patients with histologically confirmed oral squamous cell carcinoma of the oral cavity, without regional lymph node metastasis and without distant metastasis.
Participants will undergo saliva sample collection before any OSCC-specific oncological treatment.
No experimental intervention will be administered.
|
Participants will undergo saliva sample collection using a sterile disposable absorbent salivary swab before any OSCC-specific oncological treatment.
Salivary samples will be analyzed to measure interleukin-6 levels.
Available biological material will also be used to analyze selected interleukin gene polymorphisms, including IL6, IL1B, IL10, IL8/CXCL8, and IL1RN.
No experimental treatment will be administered, and the study procedures will not modify the standard diagnostic or therapeutic pathway.
Outros nomes:
|
|
OSCC N+M0
Adult patients with histologically confirmed oral squamous cell carcinoma of the oral cavity, with regional lymph node metastasis and without distant metastasis.
Participants will undergo saliva sample collection before any OSCC-specific oncological treatment.
No experimental intervention will be administered.
|
Participants will undergo saliva sample collection using a sterile disposable absorbent salivary swab before any OSCC-specific oncological treatment.
Salivary samples will be analyzed to measure interleukin-6 levels.
Available biological material will also be used to analyze selected interleukin gene polymorphisms, including IL6, IL1B, IL10, IL8/CXCL8, and IL1RN.
No experimental treatment will be administered, and the study procedures will not modify the standard diagnostic or therapeutic pathway.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in Salivary Interleukin-6 Levels Between OSCC N0M0 and OSCC N+M0 Patients
Prazo: Baseline, before any OSCC-specific oncological treatment
|
Salivary interleukin-6 levels will be compared between patients with oral squamous cell carcinoma without regional lymph node metastasis, classified as OSCC N0M0, and patients with oral squamous cell carcinoma with regional lymph node metastasis, classified as OSCC N+M0.
Salivary interleukin-6 will be measured from saliva samples collected using sterile absorbent swabs and expressed as a continuous variable in pg/mL.
|
Baseline, before any OSCC-specific oncological treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Association Between Regional Lymph Node Status and Interleukin Gene Polymorphisms
Prazo: Baseline, before any OSCC-specific oncological treatment
|
The association between regional lymph node status and selected interleukin gene polymorphisms will be evaluated by comparing genotype and/or allele frequencies of IL6, IL1B, IL10, IL8/CXCL8, and IL1RN between patients with OSCC N0M0 and patients with OSCC N+M0.
Where appropriate, results will be expressed as odds ratios for regional lymph node metastasis.
|
Baseline, before any OSCC-specific oncological treatment
|
|
Association Between Interleukin Gene Polymorphisms and Salivary Interleukin-6 Levels
Prazo: Baseline, before any OSCC-specific oncological treatment
|
The association between selected interleukin gene polymorphisms and salivary interleukin-6 levels will be assessed by comparing salivary interleukin-6 concentrations across genotype groups and/or through regression models using salivary interleukin-6 as a continuous dependent variable.
Salivary interleukin-6 will be expressed in pg/mL.
|
Baseline, before any OSCC-specific oncological treatment
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IL6-OSCC-2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .